Illumina, Inc.

Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

Retrieved on: 
Tuesday, July 18, 2023
University, Genomics, Boston University, Acquisition, Automation, Chairperson, NanoString Technologies, Growth, Northeastern University, Illumina, Inc., Industrial design, Management, Biology

Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee.

Key Points: 
  • Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee.
  • “We are very excited to welcome Kirk to our Board of Directors,” said Robert Spignesi, President and Chief Executive Officer.
  • “Kirk is an experienced executive and board director with a proven track record of leadership in the life sciences industry.
  • Mr. Schwartz added, “Kirk is an exceptional leader and my fellow Board members and I are excited to welcome him as our new Board Chair.

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck

Retrieved on: 
Tuesday, July 18, 2023
DNA, VUMC, Probability, Genetic distance, Therapy, Genetics, AGD, Vanderbilt University Medical Center, Genomics, Doctor of Philosophy, AstraZeneca, Vanderbilt University School of Medicine, MD, Data, SAN, AbbVie, Illumina, Inc., Drug discovery, WGS, Biology, Merck, Security (finance), Form 10-K, Disease, Pharmaceutical industry, Amgen, Illumina, Bayer

SAN DIEGO, July 18, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced the five founding members of the Alliance for Genomic Discovery (AGD). The multiyear agreement aims to accelerate development of therapeutics through large-scale genomics and the establishment of a preeminent clinical genomic resource. Member organizations AbbVie, Amgen, AstraZeneca, Bayer, and Merck will co-fund the whole-genome sequencing (WGS) of 250,000 samples and have access to the resulting data for use in drug discovery and therapeutic development. 

Key Points: 
  • The multiyear agreement aims to accelerate development of therapeutics through large-scale genomics and the establishment of a preeminent clinical genomic resource.
  • Member organizations AbbVie, Amgen, AstraZeneca, Bayer, and Merck will co-fund the whole-genome sequencing (WGS) of 250,000 samples and have access to the resulting data for use in drug discovery and therapeutic development.
  • "We are thrilled to welcome these esteemed companies as the founding cohort in the Alliance for Genomic Discovery," said Joydeep Goswami, chief financial officer and chief strategy and corporate development officer of Illumina.
  • With today's announcement, deCODE genetics, a wholly owned subsidiary of Amgen, will sequence the remaining samples for the Alliance.

Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery

Retrieved on: 
Tuesday, July 11, 2023
DNA, LPA, NGS, Cardiovascular disease, Baylor University, Research, Genomics, Human Genome Sequencing Center, HBA, Machine learning, SAN, Illumina, Inc., Algorithm, Informatics, Medicine, Drug discovery, SNV, Baylor College of Medicine, Health, RH, CYP21A2, DSM-IV codes, Genome, Antibiotics, Typesetting, Pharmaceutical industry, Software, Mosaic, Illumina, LP

SAN DIEGO, July 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the latest version of DRAGEN™ software for analysis of next-generation sequencing data. DRAGEN 4.2 expands award-winning accuracy combined with its renowned flexibility and scalability to enable efficient workflows and extract meaningful insights from genomic data.

Key Points: 
  • "DRAGEN 4.2 continues to push the boundaries of accuracy and comprehensiveness for secondary analysis," said Rami Mehio, vice president of Software and Informatics at Illumina.
  • "As we pass DRAGEN's fifth year at Illumina, we see rapid adoption of genomics in clinical settings, precision medicine and research.
  • DRAGEN, with its ability to perform high quality, fast, accurate and comprehensive NGS analysis workflows, is ideally suited to support the healthcare and research industry in these endeavors.
  • DRAGEN v4.2 improves identification of genetic disease causes, drug discovery and population genomics with:
    Improved machine learning algorithms for greater sensitivity and precision of variant calls.

Precision Spraying Pioneer Greeneye Technology Appoints Ori Sarfaty as VP R&D

Retrieved on: 
Tuesday, July 11, 2023
Farmer, Mechanical engineering, New product development, Boston University, Biomedical engineering, Mechanical, Research and development, TEL, Applied Materials, Acquisition, Weed control, Machine learning, Illumina, Inc., Robotics, D, Agriculture, Greeneye, Research, Technion – Israel Institute of Technology

TEL AVIV, Israel, July 11, 2023 /PRNewswire/ -- Greeneye Technology, the pioneer of AI-enabled precision spraying technology that is proven to reduce herbicide use by up to 94%, has appointed Ori Sarfaty to the role of Vice President of Research and Development.

Key Points: 
  • TEL AVIV, Israel, July 11, 2023 /PRNewswire/ -- Greeneye Technology, the pioneer of AI-enabled precision spraying technology that is proven to reduce herbicide use by up to 94%, has appointed Ori Sarfaty to the role of Vice President of Research and Development.
  • Sarfaty comments: "I am delighted to join Greeneye Technology at such a pivotal time in the company's development.
  • Greeneye has already achieved what many thought was not possible – successfully launching a precision spraying system that is proven to significantly reduce herbicide use while seamlessly integrating into farmers' existing operations.
  • Greeneye Technology is transforming weed control with its breakthrough precision spraying technology that is proven to cut herbicide use by up to 94% and reduce costs by more than 60% while delivering the same level of efficacy compared to broadcast spraying[1].

Precision Spraying Pioneer Greeneye Technology Appoints Ori Sarfaty as VP R&D

Retrieved on: 
Tuesday, July 11, 2023
Farmer, Mechanical engineering, New product development, Boston University, Biomedical engineering, Mechanical, Research and development, TEL, Applied Materials, Acquisition, Weed control, Machine learning, Illumina, Inc., Robotics, D, Agriculture, Greeneye, Research, Technion – Israel Institute of Technology

TEL AVIV, Israel, July 11, 2023 /PRNewswire/ -- Greeneye Technology, the pioneer of AI-enabled precision spraying technology that is proven to reduce herbicide use by up to 94%, has appointed Ori Sarfaty to the role of Vice President of Research and Development.

Key Points: 
  • TEL AVIV, Israel, July 11, 2023 /PRNewswire/ -- Greeneye Technology, the pioneer of AI-enabled precision spraying technology that is proven to reduce herbicide use by up to 94%, has appointed Ori Sarfaty to the role of Vice President of Research and Development.
  • Sarfaty comments: "I am delighted to join Greeneye Technology at such a pivotal time in the company's development.
  • Greeneye has already achieved what many thought was not possible – successfully launching a precision spraying system that is proven to significantly reduce herbicide use while seamlessly integrating into farmers' existing operations.
  • Greeneye Technology is transforming weed control with its breakthrough precision spraying technology that is proven to cut herbicide use by up to 94% and reduce costs by more than 60% while delivering the same level of efficacy compared to broadcast spraying[1].

Multicancer Screening Global Market Report 2023: Need for Early Detection of Cancer Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 7, 2023
Health, Oncology, Medical Devices, CE, DNA, Prevalence, Urine, 2005 in television, Food and Drug Administration, Liquid biopsy, Cancer, RNA, Biomarker, GRAIL, Patient, Physician, Blood, LDT, Growth, Region, FDA, Food, Saliva, Illumina, Inc., Pharmaceutical industry, Medical imaging

The global multicancer screening market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032.

Key Points: 
  • The global multicancer screening market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032.
  • The growth in the global multicancer screening market is expected to be driven by the increased use of liquid biopsy testing and increasing prevalence of cancers.
  • Multicancer screening is a cancer screening test that has the potential to screen for more than one cancer type with a single test.
  • Some multicancer screening tests can also identify the tissue of the origin of cancer, while others need imaging tests to verify the origin.

Single-cell Analysis Market worth $7.1 billion | MarketsandMarkets

Retrieved on: 
Thursday, June 22, 2023
Prevalence, Genomics, B cell, Merck Group, Biomedical Research, DiaSorin, Patient, Conditional sentence, Commercial, Automation, Tissue, Bio-Rad Laboratories, Single-cell analysis, Research, Infection, Gene expression, Danaher Corporation, Biology, Machine learning, Medicine, Growth, BD, DNA, Corning Inc., Genetics, Cancer, Cell, Biomarker, Becton, Dickinson and Company headquarters, Participation, Algorithm, Agilent Technologies, Flow cytometry, PAT, SME, Illumina, Inc., QIAGEN, Process analytical technology, Sartorius AG, Standard BioTools, RNA, Promega, Computation, Oxford Nanopore Technologies, Retail, Mobile phone, Video game, Pharmaceutical industry, Fine chemical, Marketing, Microscope

The research applications segment accounted for the largest share of the application segment in the single-cell analysis market in 2022.

Key Points: 
  • The research applications segment accounted for the largest share of the application segment in the single-cell analysis market in 2022.
  • Based on applications, the single-cell analysis market is categorized into two segments—medical applications and research applications.
  • The Asia Pacific region is estimated to grow at the highest CAGR in the single-cell analysis market during the forecast period.
  • Tracking the product portfolios of prominent market players helps to analyze the products in the single-cell analysis market.

Single-cell Analysis Market worth $7.1 billion | MarketsandMarkets

Retrieved on: 
Thursday, June 22, 2023
Prevalence, Genomics, B cell, Merck Group, Biomedical Research, DiaSorin, Patient, Conditional sentence, Commercial, Automation, Tissue, Bio-Rad Laboratories, Single-cell analysis, Research, Infection, Gene expression, Danaher Corporation, Biology, Machine learning, Medicine, Growth, BD, DNA, Corning Inc., Genetics, Cancer, Cell, Biomarker, Becton, Dickinson and Company headquarters, Participation, Algorithm, Agilent Technologies, Flow cytometry, PAT, SME, Illumina, Inc., QIAGEN, Process analytical technology, Sartorius AG, Standard BioTools, RNA, Promega, Computation, Oxford Nanopore Technologies, Retail, Mobile phone, Video game, Pharmaceutical industry, Fine chemical, Marketing, Microscope

The research applications segment accounted for the largest share of the application segment in the single-cell analysis market in 2022.

Key Points: 
  • The research applications segment accounted for the largest share of the application segment in the single-cell analysis market in 2022.
  • Based on applications, the single-cell analysis market is categorized into two segments—medical applications and research applications.
  • The Asia Pacific region is estimated to grow at the highest CAGR in the single-cell analysis market during the forecast period.
  • Tracking the product portfolios of prominent market players helps to analyze the products in the single-cell analysis market.

Illumina Ventures to Launch Illumina® Ventures Labs

Retrieved on: 
Tuesday, June 20, 2023
Research, Finance, Genetics, Professional Services, Stem Cells, Biotechnology, Start-Up, Health, Science, Partnership, NGS, Genomics, Organization, Investment, Accelerator, Illumina, Inc., Cryptocurrency, Pharmaceutical industry, Illumina

Illumina Ventures, a leading genomics and precision health venture firm, today announced plans to launch Illumina® Ventures Labs.

Key Points: 
  • Illumina Ventures, a leading genomics and precision health venture firm, today announced plans to launch Illumina® Ventures Labs.
  • Building on the foundation of the Illumina Accelerator program, Illumina Ventures Labs will operate and provide access to fully equipped genomics labs in the US and the UK, mentorship, and seed financing to attract a broad range of genomics related start-ups.
  • Illumina, Inc. will provide the start-ups with technical guidance from its subject matter experts and will provide Illumina Ventures Labs access to its next-generation sequencing (NGS) platforms, in lieu of operating its Accelerator program.
  • “This expansion of our relationship with Illumina is a continuation of Illumina Ventures’ strategy to pursue earlier stage investing,” said Nick Naclerio, Founding Partner of Illumina Ventures.

Illumina announces CEO transition plan

Retrieved on: 
Sunday, June 11, 2023
DNA, Senior, General counsel, Patient, Physician, SAN, Illumina, Inc., Growth, Health, Genome, Management, Illumina

Charles Dadswell, Senior Vice President and General Counsel, has been named interim CEO while the Board of Directors conducts a search for a new CEO.

Key Points: 
  • Charles Dadswell, Senior Vice President and General Counsel, has been named interim CEO while the Board of Directors conducts a search for a new CEO.
  • We are confident Illumina can continue to execute on its goals while we conduct and complete a CEO search process."
  • On behalf of patients, clinicians and physicians everywhere, I'd like to thank the thousands of Illumina employees who made it happen," said Mr. deSouza.
  • The Board of Directors is conducting a search for a new CEO looking at internal and external candidates.